SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Open accessThe DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular (CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of antidiabetic medication that inhibit the absorption of glucose from the proximal tubule of the kidney and hence cause glycosuria. Four SGLT2i are currently commercially available in many countries: canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. SGLT2i reduce glycated hemoglobin by 0.5%–1.0% and have shown favorable effects on body weight, blood pressure, lipid profile, arterial stiffness and endothelial function. More importantly, SGLT2i have demonstrated impressive cardioprotective and renoprotective effects. The main mechanisms underlying their cardioprotective effects have been attributed to improvement in cardiac cell metabolism, improvement in ventricular loading conditions, inhibition of the Na+/H+ exchange in the myocardial cells, alteration in adipokines and cytokines production, as well as reduction of cardiac cells necrosis and cardiac fibrosis. The main adverse events of SGLT2i include urinary tract and genital infections, as well as euglycemic diabetic ketoacidosis. Concerns have also been raised about the association of SGLT2i with lower limb amputations, Fournier gangrene, risk of bone fractures, female breast cancer, male bladder cancer, orthostatic hypotension, and acute kidney injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SGLT2-i improves the metabolic profile in patients with diabetes increasing glycosuria by inhibiting glucose reuptake in the renal proximal tubule. As a result, they induce a reduction of both arterial pressure and body weight, demonstrating impressive cardio- and nephro-protective effects [59].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · cited 10×
“The EMPA-REG OUTCOME trial and the CANVAS program showed that the administration of Empa or Cana increased both low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) when compared with placebo [65,68].”
BackgroundMethodResultInfluentialAhmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663 · cited 5×
“Nevertheless, it is unlikely that the latter can fully explain the impressive effect of SGLT2i on renal outcomes since patients in these studies were treated with RAASi [87].”
BackgroundInfluentialOLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 14×
“Nevertheless, it is unlikely that the latter can fully explain the impressive effect of SGLT2i on renal outcomes since patients in these studies were treated with RAASi [87].”
BackgroundMethodResultInfluential10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382 · cited 10×
“Results of DECLARE-TIMI, nevertheless, did not confirm a higher cancer risk with Dapa [69].”
BackgroundMethodResultInfluentialCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“Administration of Cana led to the reduction of end-stage renal disease, doubling of the serum creatinine level, or death from renal or CV causes [85].”
BackgroundThe ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Prediction of Cardiovascular Events and All-Cause Mortality With Arterial Stiffness
Vlachopoulos, C., Aznaouridis, K., & Stefanadis, C. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.061 · Cited by 4,165
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · cited 7×
“The Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (Dapa-CKD) examines the effect of Dapa on renal function in people with CKD and is estimated to be completed in November 2020 [86].”
BackgroundMethodInfluentialSCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
PEDERSEN, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,106
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 4×
“Furthermore, SGLT2i significantly reduced the risk of MI by 11% and CV mortality by 16%, whereas SGLT2i had no effect on strokes [71].”
BackgroundMethodInfluentialMozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., Das, S. R., de Ferranti, S., Després, J.-P., Fullerton, H. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000366 · Cited by 2,466 · cited 1×
“The leading cause of morbidity and mortality in the diabetic population remains cardiovascular (CV) disease, which is estimated to be 2-4 times more common in patients with DM when compared with people without DM [2,3].”
BackgroundMyocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179 · cited 1×
“The increased utilization of this substrate as an adenosine triphosphate (ATP) generator may lead to overproduction of FFA intermediates, which may promote lipotoxicity and impairment in sarcoplasmatic reticulum, further resulting in ventricular stiffness and dysfunction [102,103,106].”
BackgroundAdler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133 · cited 1×
“It is widely known that the reduction of arterial blood pressure (BP) is associated with reduction of CV morbidity and mortality in patients with DM [79].”
BackgroundSuppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor
Shimazu, T., Hirschey, M. D., Newman, J., He, W., Shirakawa, K., Le Moan, N., Grueter, C. A., Lim, H., Saunders, L. R., Stevens, R. D., et al. (2013) · Science · doi:10.1126/science.1227166 · Cited by 1,777
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430 · cited 1×
“Apart from the proximal tubule epithelium, SGLT2s are located in pancreatic a-cells and in the cerebellum, while SGLT1s are more widely distributed to kidneys, intestine, heart, lungs and skeletal muscles [12,13].”
BackgroundFox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401 · cited 1×
“CKD increases CV risk in people with and without DM [83].”
BackgroundHeerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376 · cited 1×
“Apart from the proximal tubule epithelium, SGLT2s are located in pancreatic a-cells and in the cerebellum, while SGLT1s are more widely distributed to kidneys, intestine, heart, lungs and skeletal muscles [12,13].”
BackgroundCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329 · cited 2×
“Furthermore, other mechanisms such as increased erythropoietin and thereby hematocrit, due to decreased renal cortical oxygen tension or the interaction between SGLT2 and the sodium–hydrogen exchanger (NHE), have been proposed [89].”
BackgroundObesity and Cardiovascular Disease
Ortega, F. B., Lavie, C. J., & Blair, S. N. (2016) · Circulation Research · doi:10.1161/circresaha.115.306883 · Cited by 1,202 · cited 1×
“Obesity is an independent risk factor for CV events [75].”
BackgroundMetabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 1×
“SGLT2i do not have effect on resting or postprandial energy expenditure, hence, the difference between expected weight loss and observed weight loss implies gradual compensatory increase in caloric intake [76,77].”
BackgroundSGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999 · cited 3×
“A healthy heart is able to rapidly switch from one source to another depending on substrate availability, workload, hormonal milieu and level of tissue perfusion [102].”
BackgroundCV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 860 · cited 2×
“5, 5, 10 mg or placebo once daily for a period of 24 weeks [25].”
BackgroundDapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029190 · Cited by 813 · cited 2×
“Treatment with SGLT2i was associated with significantly lower rates of hospitalization for HF, all-cause death, and hospitalization HF or all-cause death [74].”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 716 · cited 1×
“5, 5 and, 10 mg Dapa, respectively [24].”
Pathophysiology of diabetic dyslipidaemia: where are we?
Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708
Baartscheer, A., Schumacher, C. A., Wüst, R. C. I., Fiolet, J. W. T., Stienen, G. J. M., Coronel, R., & Zuurbier, C. J. (2017) · Diabetologia · doi:10.1007/s00125-016-4134-x · Cited by 661 · cited 1×
“cytoplasmatic calcium and sodium, while mitochondrial calcium levels were increased [123].”
BackgroundMeng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634 · cited 8×
“The third agent of this class was Empa, which has the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold) among the commercially available SGLT2i [21].”
BackgroundInfluentialStenlöf, K., Cefalu, W. T., Kim, K. ‐., Alba, M., Usiskin, K., Tong, C., Canovatchel, W., & Meininger, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12054 · Cited by 614 · cited 2×
“As expected, no similar effect was reported with placebo [39].”
BackgroundResultUthman, L., Baartscheer, A., Bleijlevens, B., Schumacher, C. A., Fiolet, J. W. T., Koeman, A., Jancev, M., Hollmann, M. W., Weber, N. C., Coronel, R., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4509-7 · Cited by 610 · cited 1×
“The NHE isoform 1 is expressed in the myocardium and a tempting hypothesis is that SGLT2i may directly inhibit this exchanger, which is upregulated in patients with HF [120,121].”
BackgroundGrempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608 · cited 1×
“The third agent of this class was Empa, which has the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold) among the commercially available SGLT2i [21].”
BackgroundRenal, metabolic and cardiovascular considerations of SGLT2 inhibition
DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.170 · Cited by 553 · cited 9×
“This threshold is referred to as the “threshold for glycosuria” [10].”
BackgroundInfluentialNauck, M. A., Del Prato, S., Meier, J. J., Durán-García, S., Rohwedder, K., Elze, M., & Parikh, S. J. (2011) · Diabetes Care · doi:10.2337/dc11-0606 · Cited by 528
Lee, T.-M., Chang, N.-C., & Lin, S.-Z. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.035 · Cited by 504
Zaccardi, F., Webb, D. R., Htike, Z. Z., Youssef, D., Khunti, K., & Davies, M. J. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12670 · Cited by 489 · cited 2×
“Even though all SGLT2i reduce BP, indirect data from a meta-analysis demonstrated that Cana 300 mg led to greater reduction of systolic BP in comparison with other SGLT2i, while no differences were reported for diastolic BP among several SGLT2i [50].”
BackgroundResultBolinder, J., Ljunggren, Ö., Johansson, L., Wilding, J., Langkilde, A. M., Sjöström, C. D., Sugg, J., & Parikh, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12189 · Cited by 482
Wu, J. H. Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., & Neal, B. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00052-8 · Cited by 474 · cited 3×
“In a meta-analysis, the risk of hypoglycemia was not significantly increased with SGLT2i versus the control group [174].”
BackgroundInfluentialWilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., Parikh, S., & for the Dapagliflozin 006 Study Group* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-6-201203200-00003 · Cited by 467
Baker, W. L., Smyth, L. R., Riche, D. M., Bourret, E. M., Chamberlin, K. W., & White, W. B. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.01.007 · Cited by 452 · cited 1×
“Nevertheless, one meta-analysis comparing Cana or Dapa with either placebo or active comparator and one comparing Empa with placebo, did not confirm a significant volume depletion with SGLT2i [91,178].”
ResultRoden, M., Weng, J., Eilbracht, J., Delafont, B., Kim, G., Woerle, H. J., & Broedl, U. C. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70084-6 · Cited by 450 · cited 2×
“The authors of the study suggested that the extent of Empa’s effect depends partially on the degree of glycemia [51].”
BackgroundKetone body metabolism and cardiovascular disease
Cotter, D. G., Schugar, R. C., & Crawford, P. A. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00646.2012 · Cited by 440
Rosenstock, J., Vico, M., Wei, L., Salsali, A., & List, J. F. (2012) · Diabetes Care · doi:10.2337/dc11-1693 · Cited by 408 · cited 2×
“Another study examined the glycemic effect of Dapa when added in patients with T2DM inadequately controlled with pioglitazone [33].”
BackgroundResultStrojek, K., Yoon, K. H., Hruba, V., Elze, M., Langkilde, A. M., & Parikh, S. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01434.x · Cited by 406 · cited 3×
“8%), most likely due to the combination of improved glycemic control with Dapa and the hypoglycemic effects of glimepiride [31].”
BackgroundInfluentialHäring, H.-U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Broedl, U. C., Woerle, H. J., & on behalf of the EMPA-REG MET Trial Investigators (2014) · Diabetes Care · doi:10.2337/dc13-2105 · Cited by 400 · cited 1×
“In addition, Haring and coworkers performed a study to investigate the efficacy and tolerability of Empa as an add-on to metformin monotherapy in patients with T2DM [52].”
Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences
Gallo, L. A., Wright, E. M., & Vallon, V. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114561992 · Cited by 395
Kovacs, C. S., Seshiah, V., Swallow, R., Jones, R., Rattunde, H., Woerle, H. J., Broedl, U. C., & on behalf of the EMPA‐REG PIO™ trial investigators (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12188 · Cited by 387 · cited 1×
“Similar improvements in HbA1c were demonstrated in a 24-week RCT in which Empa was added on people with T2DM receiving pioglitazone with or without metformin [54].”
MethodNomura, S., Sakamaki, S., Hongu, M., Kawanishi, E., Koga, Y., Sakamoto, T., Yamamoto, Y., Ueta, K., Kimata, H., Nakayama, K., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100332n · Cited by 385 · cited 8×
“The third agent of this class was Empa, which has the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold) among the commercially available SGLT2i [21].”
BackgroundInfluentialRidderstråle, M., Andersen, K. R., Zeller, C., Kim, G., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70120-2 · Cited by 378 · cited 1×
“In terms of head-to-head trials, one study compared Empa with glimepiride for a period of 2 years in people with T2DM that were inadequately controlled with metformin [58].”
MethodThe effect of dapagliflozin treatment on epicardial adipose tissue volume
Sato, T., Aizawa, Y., Yuasa, S., Kishi, S., Fuse, K., Fujita, S., Ikeda, Y., Kitazawa, H., Takahashi, M., Sato, M., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0658-8 · Cited by 378
Solini, A., Giannini, L., Seghieri, M., Vitolo, E., Taddei, S., Ghiadoni, L., & Bruno, R. M. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0621-8 · Cited by 373 · cited 2×
“Authors suggested that Dapa might have a direct effect on the vascular endothelium since known parameters that cause endothelial dysfunction, such as hyperglycemia and sympathetic activation, were not found to affect endothelial function [97].”
BackgroundMethodEmpagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes
Häring, H.-U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Woerle, H. J., Broedl, U. C., & on behalf of the EMPA-REG METSU Trial Investigators (2013) · Diabetes Care · doi:10.2337/dc12-2673 · Cited by 371 · cited 2×
“Hypoglycemic events were reported more often in the group treated with Empa when compared with placebo [53].”
BackgroundResultUeda, P., Svanström, H., Melbye, M., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., & Pasternak, B. (2018) · BMJ · doi:10.1136/bmj.k4365 · Cited by 367 · cited 10×
“Data from a real-world setting showed that among patients with T2DM, the addition of Cana resulted in a reduction of HbA1c by 1.16%, while the addition of GLP1-RA by 1.21% [49].”
BackgroundResultInfluentialBirkeland, K. I., Jørgensen, M. E., Carstensen, B., Persson, F., Gulseth, H. L., Thuresson, M., Fenici, P., Nathanson, D., Nyström, T., Eriksson, J. W., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30258-9 · Cited by 362 · cited 5×
“performed an observational analysis of data from Denmark, Norway and Sweden [73].”
BackgroundMethodResultInfluentialGoldenberg, R. M., Berard, L. D., Cheng, A. Y. Y., Gilbert, J. D., Verma, S., Woo, V. C., & Yale, J.-F. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.11.002 · Cited by 354 · cited 1×
“DKA related to SGLT2i may be accompanied by low glucose levels (<250 mg/dL), due to the glycosuric effect of these drugs, and hence, it is called euglycemic [134].”
BackgroundBailey, C. J., Gross, J. L., Hennicken, D., Iqbal, N., Mansfield, T. A., & List, J. F. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-43 · Cited by 352 · cited 1×
“The glucose-lowering effect of Dapa was sustained in the 78-week extension of the trial [26].”
BackgroundPhysiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
Ghezzi, C., Loo, D. D. F., & Wright, E. M. (2018) · Diabetologia · doi:10.1007/s00125-018-4656-5 · Cited by 348 · cited 1×
“Phlorizin was isolated from apple trees in 1835 and is the first natural SGLT inhibitor that has high-affinity, specific, and competitive inhibitory activity for both SGLT1 and SGLT2 [17,18].”
BackgroundMazidi, M., Rezaie, P., Gao, H., & Kengne, A. P. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004007 · Cited by 347
Packer, M., Anker, S. D., Butler, J., Filippatos, G., & Zannad, F. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.2275 · Cited by 336
Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor
Fralick, M., Schneeweiss, S., & Patorno, E. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1701990 · Cited by 334
Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13648 · Cited by 330 · cited 7×
“The Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (Dapa-CKD) examines the effect of Dapa on renal function in people with CKD and is estimated to be completed in November 2020 [86].”
BackgroundInfluentialWilding, J. P. H., Charpentier, G., Hollander, P., González‐Gálvez, G., Mathieu, C., Vercruysse, F., Usiskin, K., Law, G., Black, S., Canovatchel, W., et al. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12322 · Cited by 317
Sattar, N., McLaren, J., Kristensen, S. L., Preiss, D., & McMurray, J. J. (2016) · Diabetologia · doi:10.1007/s00125-016-3956-x · Cited by 309
Ogawa, W., & Sakaguchi, K. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12401 · Cited by 307 · cited 2×
“The net result is an increase in glucagon to insulin ratio, which promotes lipolysis and ketogenesis [107].”
BackgroundDeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., Morrow, L. A., Leslie, B. R., Boulton, D. W., Ching, A., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0387 · Cited by 293 · cited 1×
“Studies have shown that people with DM have elevated levels of renal threshold for glycosuria and increased renal glucose reabsorption capacity, and this applies even for patients with good glycemic control [10,15].”
BackgroundWilding, J. P. H., Woo, V., Rohwedder, K., Sugg, J., Parikh, S., & for the Dapagliflozin 006 Study Group (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12187 · Cited by 291
Jabbour, S. A., Hardy, E., Sugg, J., Parikh, & for the Study 10 Group (2014) · Diabetes Care · doi:10.2337/dc13-0467 · Cited by 286
Possible adverse effects of SGLT2 inhibitors on bone
Taylor, S. I., Blau, J. E., & Rother, K. I. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70227-x · Cited by 283
Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
Clar, C., Gill, J. A., Court, R., & Waugh, N. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001007 · Cited by 282
Puckrin, R., Saltiel, M.-P., Reynier, P., Azoulay, L., Yu, O. H. Y., & Filion, K. B. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1116-0 · Cited by 278 · cited 6×
“The frequency of UTIs was not significantly increased with SGLT2i versus either DPP4i or GLP1-RA in two studies [144,145].”
BackgroundResultInfluentialGenital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria
Geerlings, S., Fonseca, V., Castro-Diaz, D., List, J., & Parikh, S. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.12.052 · Cited by 274 · cited 1×
“The higher urine glucose levels due to the glycosuric effect of SGLT2i, predisposes patients to urinary tract and genital infections [140].”
BackgroundLiu, J., Li, L., Li, S., Jia, P., Deng, K., Chen, W., & Sun, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-02733-w · Cited by 273 · cited 6×
“The frequency of UTIs was not significantly increased with SGLT2i versus either DPP4i or GLP1-RA in two studies [144,145].”
BackgroundResultInfluentialKetoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data
Blau, J. E., Tella, S. H., Taylor, S. I., & Rother, K. I. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2924 · Cited by 271
Garvey, W. T., Van Gaal, L., Leiter, L. A., Vijapurkar, U., List, J., Cuddihy, R., Ren, J., & Davies, M. J. (2018) · Metabolism · doi:10.1016/j.metabol.2018.02.002 · Cited by 261 · cited 1×
“showed that Cana led to a 25% reduction of serum leptin levels and to a 17% increase of serum adiponectin when compared with glimepiride [125].”
ResultForst, T., Guthrie, R., Goldenberg, R., Yee, J., Vijapurkar, U., Meininger, G., & Stein, P. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12273 · Cited by 255
Rosenstock, J., Jelaska, A., Zeller, C., Kim, G., Broedl, U. C., Woerle, H. J., & on behalf of the EMPA‐REG BASAL trial investigators (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12503 · Cited by 252 · cited 2×
“Finally, Rosenstock and colleagues investigated the efficacy and tolerability of Empa when added in patients treated with basal insulin [57].”
BackgroundSGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
Fadini, G. P., Bonora, B. M., & Avogaro, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4301-8 · Cited by 242 · cited 1×
“A predominance of female gender among DKA cases was also observed [137].”
BackgroundStorgaard, H., Gluud, L. L., Bennett, C., Grøndahl, M. F., Christensen, M. B., Knop, F. K., & Vilsbøll, T. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166125 · Cited by 237 · cited 1×
“Cana was associated with the largest effects on serum lipids [92].”
BackgroundLeiter, L. A., Yoon, K.-H., Arias, P., Langslet, G., Xie, J., Balis, D. A., Millington, D., Vercruysse, F., Canovatchel, W., & Meininger, G. (2015) · Diabetes Care · doi:10.2337/dc13-2762 · Cited by 227 · cited 1×
“Moreover, another study showed that among patients treated with metformin, the administration of Cana 300 mg led to similar glycemic improvements compared with glimepiride after 104 weeks of intervention [47].”
ResultQiu, H., Novikov, A., & Vallon, V. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2886 · Cited by 226
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta‐analysis
Liakos, A., Karagiannis, T., Athanasiadou, E., Sarigianni, M., Mainou, M., Papatheodorou, K., Bekiari, E., & Tsapas, A. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12307 · Cited by 219 · cited 2×
“Nevertheless, one meta-analysis comparing Cana or Dapa with either placebo or active comparator and one comparing Empa with placebo, did not confirm a significant volume depletion with SGLT2i [91,178].”
ResultCardiac remodeling and failure
Fedak, P. W. M., Verma, S., Weisel, R. D., & Li, R.-K. (2005) · Cardiovascular Pathology · doi:10.1016/j.carpath.2004.12.002 · Cited by 214
Voulgari, Tentolouris, N., & Papadogiannis, D. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s11681 · Cited by 210 · cited 1×
“In a diabetic heart, this metabolic flexibility is impaired and myocardium becomes more dependent on FFA oxidation as energy fuel [104,105].”
Self-citationTang, H., Dai, Q., Shi, W., Zhai, S., Song, Y., & Han, J. (2017) · Diabetologia · doi:10.1007/s00125-017-4370-8 · Cited by 206 · cited 1×
“Of interest, a systematic review and meta-analysis observed a non-significant difference in the risk of overall cancer with SGLT2i when compared with placebo or active comparators, however, subgroup analysis revealed an increase in bladder cancer with SGLT2i in general and with Empa in particular, while a reduction in…”
ResultBaker, W. L., Buckley, L. F., Kelly, M. S., Bucheit, J. D., Parod, E. D., Brown, R., Carbone, S., Abbate, A., & Dixon, D. L. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005686 · Cited by 204
Cannon, C. P., McGuire, D. K., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Charbonnel, B., Shih, W. J., Gallo, S., Masiukiewicz, U., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.08.016 · Cited by 203 · cited 2×
“The primary outcome is the composite 3P-MACE and the key secondary outcomes are CV death or hospitalization for HF, CV death and renal death, dialysis/transplant, or doubling of serum creatinine from baseline [70].”
BackgroundRyan, P. B., Buse, J. B., Schuemie, M. J., DeFalco, F., Yuan, Z., Stang, P. E., Berlin, J. A., & Rosenthal, N. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13424 · Cited by 201 · cited 1×
“In two other studies based on real-word data, however, no significant increase in LLA was observed with SGLT2i [168,169].”
Resultvan Baar, M. J. B., van Ruiten, C. C., Muskiet, M. H. A., van Bloemendaal, L., IJzerman, R. G., & van Raalte, D. H. (2018) · Diabetes Care · doi:10.2337/dc18-0588 · Cited by 199
Hayashi, T., Fukui, T., Nakanishi, N., Yamamoto, S., Tomoyasu, M., Osamura, A., Ohara, M., Yamamoto, T., Ito, Y., & Hirano, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0491-5 · Cited by 196 · cited 6×
“The EMPA-REG OUTCOME trial and the CANVAS program showed that the administration of Empa or Cana increased both low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) when compared with placebo [65,68].”
BackgroundInfluentialKohler, S., Zeller, C., Iliev, H., & Kaspers, S. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0573-0 · Cited by 195
Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis
Nadkarni, G. N., Ferrandino, R., Chang, A., Surapaneni, A., Chauhan, K., Poojary, P., Saha, A., Ferket, B., Grams, M. E., & Coca, S. G. (2017) · Diabetes Care · doi:10.2337/dc17-1011 · Cited by 188 · cited 1×
“used data from the Mount Sinai CKD registry and the Geisinger Health System cohort and observed a lower risk for AKI among SGLT2i users versus non-users patients with DM [183].”
MethodEFFECT OF DIABETES AND INSULIN ON THE MAXIMUM CAPACITY OF THE RENAL TUBULES TO REABSORB GLUCOSE 1
Farber, S. J., Berger, E. Y., & Earle, D. P. (1951) · Journal of Clinical Investigation · doi:10.1172/jci102424 · Cited by 185 · cited 1×
“The maximum renal glucose reabsorption capacity is 375 mg per minute that corresponds to glucose levels of 300 mg/dL, while the rate at which glucose is filtered through the glomerulus is approximately 125 mg per minute [10,14].”
BackgroundRosenstock, J., Frias, J., Páll, D., Charbonnel, B., Pascu, R., Saur, D., Darekar, A., Huyck, S., Shi, H., Lauring, B., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13103 · Cited by 184
Effects of diabetes drugs on the skeleton
Meier, C., Schwartz, A. V., Egger, A., & Lecka-Czernik, B. (2016) · Bone · doi:10.1016/j.bone.2015.04.026 · Cited by 174
An update on the safety of SGLT2 inhibitors
Scheen, A. J. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1602116 · Cited by 174 · cited 8×
“A reduction in doses of insulin or SUs may be necessary when co-administered with a SGLT2i to prevent hypoglycemia.”
BackgroundInfluentialBailey, C. J., Iqbal, N., T'joen, C., & List, J. F. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01659.x · Cited by 167 · cited 1×
“Firstly, the effect of Dapa on glycemic control was examined in treatment-naïve patients with T2DM [23].”
BackgroundKang, S., Verma, S., Hassanabad, A. F., Teng, G., Belke, D. D., Dundas, J. A., Guzzardi, D. G., Svystonyuk, D. A., Pattar, S. S., Park, D. S. J., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.08.033 · Cited by 166
Tang, H. L., Li, D. D., Zhang, J. J., Hsu, Y. H., Wang, T. S., Zhai, S. D., & Song, Y. Q. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12742 · Cited by 161
Ruanpeng, D., Ungprasert, P., Sangtian, J., & Harindhanavudhi, T. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2903 · Cited by 159
Stenlöf, K., Cefalu, W. T., Kim, K.-A., Jodar, E., Alba, M., Edwards, R., Tong, C., Canovatchel, W., & Meininger, G. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.850066 · Cited by 158 · cited 1×
“The effect of Cana on HbA1c, FPG and 2 h PPG was sustained over the 52-week extension of the trial [40].”
BackgroundVerma, S., McMurray, J. J. V., & Cherney, D. Z. I. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.1891 · Cited by 158
Kappel, B. A., Lehrke, M., Schütt, K. S., Artati, A., Adamski, J., Lebherz, C., & Marx, N. (2017) · Circulation · doi:10.1161/circulationaha.117.029166 · Cited by 157 · cited 1×
“It is also postulated that SGLT2i stimulate branched-chain amino acid (BCAA) degradation, which is impaired in HF, offering an alternative fuel source in failing diabetic myocardium [116].”
BackgroundJabbour, S., Seufert, J., Scheen, A., Bailey, C. J., Karup, C., & Langkilde, A. M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13124 · Cited by 157
Mearns, E. S., Sobieraj, D. M., White, C. M., Saulsberry, W. J., Kohn, C. G., Doleh, Y., Zaccaro, E., & Coleman, C. I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125879 · Cited by 154 · cited 1×
“89 kg), whereas Cana 100 mg does not seem to differ from other SGLT2i [78].”
BackgroundBatzias, K., Antonopoulos, A. S., Oikonomou, E. K., Siasos, G., Bletsa, E., Stampouloglou, P. K., Mistakidi, C. V., Noutsou, M., Katsiki, N., Karopoulos, P., et al. (2018) · Journal of Diabetes Research · doi:10.1155/2018/1232583 · Cited by 152 · cited 1×
“However, no safe conclusion can be drawn from one study [98].”
BackgroundSelf-citationThe diabetic heart utilizes ketone bodies as an energy source
Mizuno, Y., Harada, E., Nakagawa, H., Morikawa, Y., Shono, M., Kugimiya, F., Yoshimura, M., & Yasue, H. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.005 · Cited by 149
Terra, S. G., Focht, K., Davies, M., Frias, J., Derosa, G., Darekar, A., Golm, G., Johnson, J., Saur, D., Lauring, B., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12888 · Cited by 147 · cited 2×
“16% for Ertu 5 mg and 15 mg doses, respectively [59].”
BackgroundChoi, C. (2016) · Molecules · doi:10.3390/molecules21091136 · Cited by 146
Rosenstock, J., Chuck, L. H. S., González-Ortíz, M., Merton, K., Craig, J., Capuano, G. A., & Qiu, R. (2016) · Diabetes Care · doi:10.2337/dc15-1736 · Cited by 144 · cited 1×
“In terms of head-to-head trials, a RCT that included treatment-naive patients showed non-inferiority of Cana 100 and 300 mg, in terms of both HbA1c reduction and achievement of HbA1c < 7% in comparison with metformin [46].”
ResultMascitti, V., Maurer, T. S., Robinson, R. P., Bian, J., Boustany, C., Brandt, T. A., Collman, B. M., Kalgutkar, A. S. S., Klenotic, M. K., Leininger, M. T., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200049r · Cited by 143 · cited 9×
“has 2200-fold higher selectivity for SGLT2 than for SGLT1 [22].”
BackgroundInfluentialNyirjesy, P., Sobel, J. D., Fung, A., Mayer, C., Capuano, G., Ways, K., & Usiskin, K. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.890925 · Cited by 140
Zhang, X., Zhu, Q., Chen, Y., Li, X., Chen, F., Huang, J., & Xu, B. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007165 · Cited by 138 · cited 1×
“Another recent meta-analysis demonstrated similar results [93].”
SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review
Alicic, R. Z., Johnson, E. J., & Tuttle, K. R. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.03.022 · Cited by 135 · cited 3×
“73 m2 during the first weeks of treatment and a return to baseline values after 6–12 months [10,16].”
BackgroundYang, X., Lai, D., Zhong, X., Shen, H., & Huang, Y. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1730-x · Cited by 134 · cited 3×
“Regarding the hypoglycemic effect of Cana, a meta-analysis from two studies on treatment-naive subjects and one study on people receiving metformin monotherapy did not associate Cana 300 mg with an increased hypoglycemic risk when compared with placebo [48].”
BackgroundResultInfluentialEmpagliflozin’s Fuel Hypothesis: Not so Soon
Lopaschuk, G. D., & Verma, S. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.018 · Cited by 134
SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System
Fadini, G. P., & Avogaro, A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30257-7 · Cited by 134 · cited 1×
“In a pharmacovigilance analysis of FAERS data, an increased risk of LLA was observed with Cana, but not with Empa or Dapa [167].”
BackgroundYuan, Ž., DeFalco, F., Ryan, P. B., Schuemie, M. J., Stang, P., Berlin, J. A., Desai, M. G., & Rosenthal, N. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13115 · Cited by 132
Søfteland, E. W., Meier, J. J., Vangen, B., Toorawa, R., Maldonado‐Lutomirsky, M., & Broedl, U. C. (2016) · Diabetes Care · doi:10.2337/dc16-1347 · Cited by 130 · cited 2×
“In addition, another study evaluated the efficacy of Empa versus placebo when added in patients with inadequate glycemic control treated with linagliptin and metformin [55].”
BackgroundEnergy balance and metabolic changes with sodium‐glucose co‐transporter 2 inhibition
Rajeev, S. P., Cuthbertson, D. J., & Wilding, J. P. H. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12578 · Cited by 123 · cited 5×
“SGLT2i do not have effect on resting or postprandial energy expenditure, hence, the difference between expected weight loss and observed weight loss implies gradual compensatory increase in caloric intake [76,77].”
BackgroundInfluentialCardiac remodeling and failure
Fedak, P. W. M., Verma, S., Weisel, R. D., & Li, R.-K. (2005) · Cardiovascular Pathology · doi:10.1016/j.carpath.2005.01.005 · Cited by 120
SGLT2 Inhibitors: Benefit/Risk Balance
Scheen, A. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0789-4 · Cited by 119
Bonora, B. M., Avogaro, A., & Fadini, G. P. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13012 · Cited by 118
Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
Kaplan, A., Abidi, E., EL‐Yazbi, A. F., Eid, A. H., Booz, G. W., & Zouein, F. A. (2018) · Heart Failure Reviews · doi:10.1007/s10741-017-9665-9 · Cited by 114 · cited 1×
“The increased utilization of this substrate as an adenosine triphosphate (ATP) generator may lead to overproduction of FFA intermediates, which may promote lipotoxicity and impairment in sarcoplasmatic reticulum, further resulting in ventricular stiffness and dysfunction [102,103,106].”
BackgroundHollander, P. A., Liu, J., Hill, J., Johnson, J. R., Jiang, Z. W., Golm, G. T., Huyck, S. B., Terra, S. G., Mancuso, J. P., Engel, S. S., et al. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0354-4 · Cited by 112 · cited 1×
“7% in the Ertu 15 mg, 5 mg, and glimepiride groups, respectively [63].”
BackgroundMonami, M., Nreu, B., Zannoni, S., Lualdi, C., & Mannucci, E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.04.017 · Cited by 111 · cited 1×
“780) in the prevalence of DKA with SGLT2i compared with placebo or other antidiabetic drugs [135], and similar were the results of another meta-analysis by Wang et al.”
ResultGoring, S. M., Hawkins, N., Wygant, G. D., Roudaut, M., Townsend, R., Wood, I., & Barnett, A. H. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12239 · Cited by 109 · cited 8×
“02% relative to the one induced by TZDs, while similar HbA1c reduction was observed when compared with treatment with SUs [30].”
BackgroundMethodResultInfluentialFracture Risk After Initiation of Use of Canagliflozin: A Cohort Study
Fralick, M., Kim, S. C., Schneeweiß, S., Kim, D. H., Redelmeier, D. A., & Patorno, E. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0567 · Cited by 109
A Review on the Relationship between SGLT2 Inhibitors and Cancer
Lin, H.-W., & Tseng, C. (2014) · International Journal of Endocrinology · doi:10.1155/2014/719578 · Cited by 106 · cited 1×
“In addition, no increase in cancer prevalence was reported with either Cana or Empa [162,173].”
BackgroundSzalat, A., Perlman, A., Muszkat, M., Khamaisi, M., Abassi, Z. A., & Heyman, S. N. (2017) · Drug Safety · doi:10.1007/s40264-017-0602-6 · Cited by 106
Aronson, R., Frías, J. P., Goldman, A., Darekar, A., Lauring, B. P., & Terra, S. G. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13251 · Cited by 99 · cited 1×
“The results were maintained in the 52-week extension of the study [60].”
BackgroundSugiyama, S., Jinnouchi, H., Kurinami, N., Hieshima, K., Yoshida, A., Jinnouchi, K., Nishimura, H., Suzuki, T., MIYAMOTO, F., Kajiwara, K., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0701-17 · Cited by 92 · cited 1×
“In addition, another study with a duration of 6 months showed that the administration of Dapa increased the reactive hyperemia index, which is another marker of endothelial function [99].”
BackgroundWang, Y., Desai, M. G., Ryan, P. B., DeFalco, F., Schuemie, M. J., Stang, P., Berlin, J. A., & Yuan, Ž. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.04.004 · Cited by 91
Miller, S. S., Krumins, T., Zhou, H., Huyck, S. B., Johnson, J. R., Golm, G. T., Terra, S. G., Mancuso, J. P., Engel, S. S., & Lauring, B. P. (2018) · Diabetes Therapy · doi:10.1007/s13300-017-0358-0 · Cited by 88 · cited 3×
“Furthermore, FPG and 2 h PPG were significantly reduced in both Ertu plus sitagliptin groups in comparison with placebo [62].”
BackgroundResultSubstrate Signaling by Insulin
Kashiwaya, Y., King, M. T., & Veech, R. L. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00458-x · Cited by 86
Dawwas, G. K., Smith, S. M., & Park, H. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13477 · Cited by 83
Strojek, K., Yoon, K., Hrubá, V., Sugg, J. E., Langkilde, A. M., & Parikh, S. J. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0072-0 · Cited by 82
Pharmacological aspects of the safety of gliflozins
Faillie, J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.001 · Cited by 81 · cited 1×
“A possible explanation for an increased tumor genesis with SGLT2i, from bladder epithelium at least, could be the promotion of tumor growth by persistent glycosuria, in combination with chronic or recurrent urinary tract infections [176].”
BackgroundSun, Y.-N., Zhou, Y., Chen, X., Che, W.-S., & Leung, S.-W. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004619 · Cited by 76
Tang, H., Li, D., Zhang, J., Li, Y., Wang, T., Zhai, S., & Song, Y. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12917 · Cited by 75 · cited 7×
“In a nationwide register-based cohort study, likewise, the incidence of AKI did not differ significantly between SGLT2i and GLP1-RA users [145].”
BackgroundInfluentialThong, K. Y., YADAGIRI, M., Barnes, D., Morris, D. S., Chowdhury, T. A., Chuah, L. L., Robinson, A. M., Bain, S. C., Adamson, K., & Ryder, R. E. J. (2017) · Primary care diabetes · doi:10.1016/j.pcd.2017.06.004 · Cited by 75 · cited 1×
“Female gender and previous history of genital infection were found to increase the chance for the infection to occur [148].”
BackgroundInagaki, N., Harashima, S., Maruyama, N., Kawaguchi, Y., Goda, M., & Iijima, H. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0407-4 · Cited by 74 · cited 1×
“97% after 16 weeks of intervention [45].”
SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids
Filippas-Ntekouan, S., Tsimihodimos, V., Filippatos, T. D., Dimitriou, T., & Elisaf, M. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1541348 · Cited by 71 · cited 2×
“To sum up, SGLT2i administration is associated with a small increase in LDL-C and HDL-C levels, while triglyceride and small dense LDL levels tend to modestly decrease [94].”
BackgroundLi, D., Yang, J. Y., Wang, T., Shen, S., & Tang, H. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.02.001 · Cited by 69
Gadzhanova, S., Pratt, N. L., & Roughead, E. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.06.018 · Cited by 67
Metabolism of the failing heart and the impact of SGLT2 inhibitors
García‐Ropero, Á., Santos‐Gallego, C. G., Zafar, M. U., & Badimón, J. J. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1588886 · Cited by 67 · cited 2×
“Mitochondrial oxidative metabolism is responsible for most (95%) of the production of myocardial energy, and the normal fuel for this process is balanced among free fatty acids (FFA) (70%), glucose (20%), and, to a lesser degree, lactate, amino acids and ketone bodies [102,104].”
BackgroundRodbard, H. W., Seufert, J., Aggarwal, N., Cao, A., Fung, A., Pfeifer, M. A., & Alba, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12684 · Cited by 64 · cited 2×
“In addition, Cana resulted in significant reductions in FPG by 30 mg/dL [44].”
BackgroundArakaki, R. F. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1167570 · Cited by 61 · cited 1×
“The genital infections, however, tend to be non-severe and manageable without the need for treatment discontinuation [149,150].”
BackgroundAdimadhyam, S., Lee, T. A., Calip, G. S., Marsh, D. E. S., Layden, B. T., & Schumock, G. T. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13459 · Cited by 61
Cannon, C. P., McGuire, D. K., Pratley, R. E., Dagogo-Jack, S. E., Mancuso, J. P., Huyck, S. B., Charbonnel, B. H., Shih, W., Gallo, S., MASIUKIEWICZ, U. S., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(18)32366-0 · Cited by 59
SGLT2 inhibition and glucagon secretion in humans
Saponaro, C., Pattou, F. N., & Bonner, C. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.06.005 · Cited by 57
Katsiki, N., Dimitriadis, G., Hahalis, G. N., Παπάνας, Ν., Tentolouris, N., Triposkiadis, F. K., Tsimihodimos, V., Tsioufis, C. P., Mikhailidis, D. P., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.008 · Cited by 56
Self-citationCardiac remodeling and failure
Fedak, P. W. M., Verma, S., Weisel, R. D., Škrtić, M., & Li, R. (2005) · Cardiovascular Pathology · doi:10.1016/j.carpath.2005.03.004 · Cited by 56
Raschi, E., Parisotto, M., Forcesi, E., Plaça, M. L., Marchesini, G., Ponti, F. D., & Poluzzi, E. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.10.008 · Cited by 54 · cited 1×
“Studies based on analysis of post-marketing data led to similar conclusions [144,146,147].”
MethodANZAWA, R., Bernard, M., Tamareille, S., Baetz, D., Sylviane Confort-gouny, A., Gascard, J., Cozzone, P. J., & Feuvray, D. (2006) · Diabetologia · doi:10.1007/s00125-005-0091-5 · Cited by 51
Azharuddin, M., Adil, M., Ghosh, P., & Sharma, M. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.10.019 · Cited by 47
Blevins, T., & Farooki, A. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2017.1256747 · Cited by 45 · cited 2×
“A significant increase in serum collagen type 1 beta-carboxy telopeptide (beta-CTX), a bone resorption marker, as well as in serum osteocalcin, a bone formation marker, has also been observed with Cana [154].”
BackgroundHollander, P., Hill, J., Johnson, J., Wei Jiang, Z., Golm, G., Huyck, S., Terra, S. G., Mancuso, J. P., Engel, S. S., Lauring, B., et al. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1583450 · Cited by 45 · cited 1×
“These findings were confirmed in the extension of the study [64].”
ResultEffects of sodium glucose co-transporter 2 inhibitors on the kidney
Rocha, N. D. A., Neeland, I. J., McCullough, P. A., Toto, R. D., & McGuire, D. K. (2018) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118783756 · Cited by 43
Teta, D., Bevington, A., Brown, J. R. G., Pawluczyk, I. Z. A., Harris, K. M., & Walls, J. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000083903.18724.93 · Cited by 38
Tanaka, A., Shimabukuro, M., Okada, Y., Taguchi, I., Yamaoka‐Tojo, M., Tomiyama, H., Teragawa, H., Sugiyama, S., Yoshida, H., Sato, Y., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0532-8 · Cited by 37 · cited 1×
“An ongoing study is examining the effect of Empa on endothelium in patients with T2DM and established CV disease [100].”
BackgroundNakamura, I., Maegawa, H., Tobe, K., Tabuchi, H., & Uno, S. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1408792 · Cited by 37 · cited 1×
“Limited data are available about the risk of amputations with the rest three SGLT2i (ipragliflozin, tofogliflozin, Ertu), these inhibitors do not seem to be associated with amputations [62,170,171].”
BackgroundThe relation of glycosuria to glycaemia and the determination of the renal threshold for glucose
Himsworth, H. P. (1931) · Biochemical Journal · doi:10.1042/bj0251128 · Cited by 34
Adimadhyam, S., Schumock, G. T., Calip, G. S., Marsh, D. E. S., Layden, B. T., & Lee, T. A. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13782 · Cited by 34
Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice
Tentolouris, A., Eleftheriadou, I., Tzeravini, E., Tsilingiris, D., Paschou, S. Α., Siasos, G., & Tentolouris, N. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190119154152 · Cited by 34 · cited 1×
“Apart from human studies, in vitro studies have reported that SGLT2i have a beneficial effect on endothelial function [101].”
BackgroundSelf-citationYang, T., Lü, M., Ma, L., Zhou, Y. F., & Cui, Y. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1923-y · Cited by 31 · cited 2×
“Similarly, FPG was reduced by 27 mg/dL and by 32 mg/dL, respectively [41].”
BackgroundAdvancing pharmacotherapy for diabetic foot ulcers
Eleftheriadou, I., Tentolouris, A., Tentolouris, N., & Παπάνας, Ν. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1598378 · Cited by 31
Self-citationTentolouris, A., Eleftheriadou, I., Athanasakis, K., Kyriopoulos, J. E., Tsilimigras, D. I., Grigoropoulou, P., Doupis, J., & Tentolouris, N. (2018) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2018.04.008 · Cited by 30 · cited 1×
“The leading cause of morbidity and mortality in the diabetic population remains cardiovascular (CV) disease, which is estimated to be 2-4 times more common in patients with DM when compared with people without DM [2,3].”
BackgroundSelf-citationKang, S., Verma, S., Teng, G., Belke, D. D., Svystonyuk, D. A., Guzzardi, D. G., Park, D., Turnbull, J., Malik, G., & Fedak, P. W. M. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.07.330 · Cited by 28 · cited 1×
“provided data that Empa suppresses pro-fribrotic markers such as type I collagen, a-smooth muscle actin, connective tissue growth factor and matrix metalloproteinase 2 and attenuates TFG-β1-induced fibroblasts activation [130].”
BackgroundTerauchi, Y., Tamura, M., Senda, M., Gunji, R., & Kaku, K. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13213 · Cited by 27
Mustroph, J., Lücht, C. M., Wagemann, O., Sowa, T., Hammer, K. P., Sag, C. M., Tarnowski, D., Holzamer, A., Pabel, S., Beuthner, B. E., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4819-z · Cited by 26
Terauchi, Y., Utsunomiya, K., Yasui, A., Seki, T., Cheng, G., Shiki, K., & Lee, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0604-8 · Cited by 26 · cited 1×
“A recently published trial examined the efficacy of Empa when added in subjects treated with liraglutide [56].”
BackgroundJörgens, V. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1206-z · Cited by 23 · cited 1×
“The inhibition of SGLT2 is not a novel approach since it was introduced 130 years ago by Belgian and French scientists [8].”
BackgroundUpdate on Cardiovascular Effects of Older and Newer Anti-diabetic Medications
Eleftheriadou, I., Grigoropoulou, P., Liberopoulos, E. N., Liatis, S., Kokkinos, A. D., & Tentolouris, N. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170530075533 · Cited by 21 · cited 2×
“Generally, these trials enroll subjects with high CV risk in order to gather a sufficient number of CV events in a short period of time [6].”
BackgroundSelf-citationWysham, C., Pilon, D., Ingham, M., Lafeuille, M. H., Émond, B., Kamstra, R. L., Pfeifer, M., & Lefèbvre, P. (2018) · Endocrine Practice · doi:10.4158/ep-2017-0066 · Cited by 16
Cited by
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Papachristoforou, E., Lambadiari, V., Maratou, E., & Makrilakis, K. (2020) · Journal of Diabetes Research · doi:10.1155/2020/7489795 · Cited by 479
Insulin resistance and cardiovascular disease
Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023) · Journal of International Medical Research · doi:10.1177/03000605231164548 · Cited by 385
Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus
Blahova, J., Martiniakova, M., Babikova, M., Kovacova, V., Mondockova, V., & Omelka, R. (2021) · Pharmaceuticals · doi:10.3390/ph14080806 · Cited by 302
Metadata
- Authors
- Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2019-08-17
- Volume
- 16
- Issue
- 16
- Pages
- 2965
- ISSN
- 1660-4601 (ISSN-L)
- PMC
- PMC6720282
- OpenAlex
- W2967960051
- Cited by
- 300
- References
- 183
- Citations by year
- 2026: 25 · 2025: 43 · 2024: 55 · 2023: 54 · 2022: 54 · 2021: 40 · 2020: 26 · 2019: 2
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- SGLT2 inhibitors, type 2 diabetes, cardioprotection, renal protection, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, glycosuria, HbA1c, arterial stiffness, endothelial function, Na+/H+ exchange, myocardial fibrosis, adverse events, lower limb amputation, acute kidney injury, cardiovascular risk
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Cardiotonic Agents, Cardiovascular System, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.